IRIS
GENTILE, Massimo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 601
NA - Nord America 521
AS - Asia 142
AF - Africa 10
Totale 1.274
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 521
IT - Italia 432
CN - Cina 98
FI - Finlandia 59
AT - Austria 34
DE - Germania 22
SG - Singapore 19
KR - Corea 17
NL - Olanda 15
CZ - Repubblica Ceca 11
GB - Regno Unito 11
SN - Senegal 8
UA - Ucraina 6
FR - Francia 5
HK - Hong Kong 3
ET - Etiopia 2
JP - Giappone 2
RO - Romania 2
HU - Ungheria 1
IE - Irlanda 1
IN - India 1
SA - Arabia Saudita 1
SE - Svezia 1
SI - Slovenia 1
TW - Taiwan 1
Totale 1.274
Salva come PNG Salva come JPEG
Città #
Florence 259
Shanghai 96
Ashburn 69
Ogden 69
Helsinki 57
Sesto Fiorentino 47
Noto 45
Vienna 31
New York 25
Chandler 19
Washington 19
Seoul 17
Naaldwijk 14
Rome 13
Dakar 8
Los Angeles 8
Rende 8
Seattle 7
Kilburn 5
Cosenza 4
Brooklyn 3
Chicago 3
Falkenstein 3
Genoa 3
Guidonia Montecelio 3
Lawrence 3
Palmi 3
Paris 3
Roxbury 3
Sassari 3
Addis Ababa 2
Ann Arbor 2
Bari 2
Bologna 2
Borgomanero 2
Bucharest 2
Gualdo Tadino 2
Hong Kong 2
Lappeenranta 2
London 2
Mestre 2
Miami 2
Milan 2
Naples 2
Paola 2
Pomigliano d'Arco 2
Romainville 2
Santa Clara 2
Tokyo 2
West Jordan 2
Boardman 1
Bremen 1
Central 1
Cirò Marina 1
Debrecen 1
Des Moines 1
Dipignano 1
Dublin 1
Frankfurt am Main 1
Inglewood 1
Kaohsiung City 1
Ljubljana 1
Mountain View 1
Riyadh 1
San Calogero 1
San Francisco 1
San Mateo 1
Santa Barbara 1
Serra San Bruno 1
Singapore 1
Udine 1
Utrecht 1
Villa San Giovanni 1
Totale 913
Salva come PNG Salva come JPEG
Nome #
Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity 68
Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapies 37
A novel phage display based platform for exosome diversity characterization 25
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 23
Ibrutinib in patients over 80 with chronic lymphocytic leukemia: a multicenter Italian cohort 22
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 21
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 21
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 21
Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma 20
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 20
Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair? 20
Iron chelation therapy 19
Elotuzumab in multiple myeloma 19
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 18
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol 18
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study 18
A novel phage display based platform for exosome diversity characterization 18
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study 17
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia 17
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 17
Myelodysplastic syndromes with ring sideroblasts 16
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study 16
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib 16
LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells 16
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 16
Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking? 16
Belantamab mafodotin in multiple myeloma 16
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 15
Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report 15
Teclistamab-cqyv in multiple myeloma 15
Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia Successfully Treated with Rituximab-Venetoclax: A Case Report 15
A progression-risk score to predict treatment free survival for early stage chronic lymphocytic leukemia patients. 14
Comparison of two scores in predicting pulmonary embolism-related adverse events in intermediate-high-risk patients: a systematic review and meta-analysis 14
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 14
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement 14
MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells 13
Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients 13
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 13
Multisystem Inflammatory Syndrome after Ad26.COV2.S vaccination 12
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study 12
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 12
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study 12
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort 12
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 12
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia 12
Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter? 12
Cerebral pheohyphomycosis due to curvularia species 11
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study 11
A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant 11
Isatuximab in multiple myeloma 11
Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature 11
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant 11
Predominant VH1-69 IgBCR Clones Show Higher Expression of CD5 in Heterogeneous Chronic Lymphocytic Leukemia Populations 11
A prognostic algorithm including a modified version of MD Anderson Cancer Center (MDACC) score predicts time to first treatment of patients with clinical monoclonal lymphocytosis (cMBL)/Rai stage 0 chronic lymphocytic leukemia (CLL) 10
Frequency and clinical relevance of coding and noncoding NOTCH1 mutations in early stage Binet A chronic lymphocytic leukemia patients 10
Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy 10
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model 10
Acalabrutinib in chronic lymphocytic leukemia 10
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma 10
Editorial: Lymphoid cells and tumor microenvironment: a functional crosstalk 10
An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. 10
A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma 10
Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities 9
Ivosidenib in acute myeloid leukemia 9
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group 9
Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement 9
Unmutated IGHV1-69 CLL Clone Displays a Distinct Gene Expression Profile by a Comparative qRT-PCR Assay 9
Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study 8
A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia. 8
Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma. 8
Targeting of mitochondrial fission through natural flavanones elicits anti-myeloma activity 8
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 7
Prednisone vs high-dose dexamethasone in newly diagnosed adult primary Immune Thrombocytopenia: a randomised trial 7
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. 7
Glasdegib for the treatment of acute myeloid leukemia 6
Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: iLeukemia 6
Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey 6
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study 6
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing 6
An increased number of individuals with clinically recognized monoclonal B-cell lymphocytosis characterizes a recent database of chronic lymphocytic leukemia Rai stage 0. 6
A non-invasive approach to monitor chronic lymphocytic leukemia engraftment in a xenograft mouse model using ultra-small superparamagnetic iron oxide-magnetic resonance imaging (USPIO-MRI) 6
An old drug with a new future: bendamustine in multiple myeloma 6
The use of ibrutinib before and after allogeneic stem cell transplantation 5
A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy 5
Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura 5
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies 5
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials 5
Le complicanze infettive nella leucemia linfatica cronica 5
Enumeration of interleukin-10-positive B cells from peripheral blood of patients with chronic lymphocytic leukemia 4
Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases 4
CNS Prophylaxis: How Far Is Routine Practice From the Guidelines? Focus on a Nationwide Survey by the Fondazione Italiana Linfomi (FIL) 4
COVID-19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients 4
Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target 4
microRNAome expression in chronic lymphocytic leukemia: comparison with normal B cell subsets and correlations with prognostic and clinical parameters 4
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 4
Complete remission through blast cell differentiation in PLZF/RARalpha-positive acute promyelocytic leukemia: in vitro and in vivo studies. 4
Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Randomized Clinical Trials 4
Zanubrutinib for the treatment of chronic lymphocytic leukemia 4
Insights into defibrotide: an updated review. 4
Chemotherapy-based regimens in multiple myeloma in 2020. 4
Totale 1.213
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.133
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.133
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20218 0 0 4 2 0 0 0 1 0 1 0 0
2021/202224 0 2 0 0 2 0 0 6 1 1 5 7
2022/2023449 6 5 3 11 8 5 282 26 19 20 50 14
2023/20241.078 36 37 248 196 97 155 81 49 122 53 4 0
Totale 1.559